Boji Medical controlling shareholder nears 1% equity reduction milestone

Guangzhou Boji Medical & Biotechnological announced that its controlling shareholder, Wang Tingchun, and parties acting in concert, including Zhao Lingli and Hengqin Guangjin Meihua Fund Management Co. Ltd. - Guangjin Meihua Fermi No. 13 Private Securities Investment Fund (Fermi No. 13), have reduced their shareholding. Between September 12, 2025, and October 17, 2025, Fermi No. 13 sold 1,161,000 shares via centralized bidding, representing 0.30% of the company's total share capital.

Following this reduction, the collective holdings of Wang Tingchun, Zhao Lingli, and Fermi No. 13 decreased from 143,430,690 shares (37.20% of total share capital) to 142,269,690 shares (36.88%). This change, combined with a passive dilution of 0.02% due to employee stock option exercises, has triggered a 1% equity change threshold.

The total reduction in holdings by the controlling shareholder and parties acting in concert since the pre-disclosure announcement amounted to a 0.32% decrease, adjusting their combined stake in the company. The company emphasizes that this equity change will not alter the company's control or impact its ongoing operations.